SPOP Suppresses Hepatocellular Carcinoma Growth and Metastasis by Ubiquitination and Proteasomal Degradation of TRAF6
Cancer Science · 2025-05 · 116 (5) · 1295-1307
DOI: 10.1111/cas.70025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 17.02.2025. Verfasst von Wenyi Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biology for Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Secon…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, TNF Receptor-Associated Factor 6, Repressor Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, the Innovative and Entrepreneurial Team of Chongqing Talents Plan.
Abstract (Originalsprache)
Tumor necrosis factor receptor‐associated factor‐6 (TRAF6) is a well‐established upstream regulator of the IKK complex, essential for the modulation of the NF‐κB (nuclear factor kappa B) signaling pathway. Aberrant activation of TRAF6 has been strongly implicated in the pathogenesis of various cancers, including hepatocellular carcinoma (HCC). The speckle type BTB/POZ protein (SPOP), an E3 ubiquitin ligase substrate‐binding adapter, constitutes a significant component of the CUL3/SPOP/RBX1 complex, which is closely linked to tumorigenesis. In this study, we demonstrated that the E3 ubiquitin ligase SPOP shielded TRAF6 from proteasomal degradation, leading to the hyperactivation of the NF‐κB pathway. Notably, a liver cancer‐associated S119N mutation in SPOP resulted in a failure to mediate the ubiquitination and subsequent degradation of TRAF6. Moreover, both gain‐of‐function and loss‐of‐function experiments revealed that SPOP inhibits the proliferation and invasion of HCC cells through the TRAF6‐NF‐κB axis in vitro and in vivo. Taken together, our findings elucidate the underpinning mechanism by which SPOP negatively regulates the stability of the TRAF6 oncoprotein, thus offering a new therapeutic target for HCC intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Molecular Biology for Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital Chongqing Medical University, Chongqing, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- the Innovative and Entrepreneurial Team of Chongqing Talents Plan
- Chongqing Medical Scientific Research Project (Joint project of Chongqing Health Commission and Science and Technology Bureau)
- Senior Medical Talents Program of Chongqing for Young and Middle aged
- Kuanren talents and Joint project of Pinnacle Disciplinary Group, the Second Affiliated Hospital of Chongqing Medical University
Zitieren
APA
Chang, W., Feng, K., Zhou, P., Gong, D., Wang, K., Huang, A., Wang, K., & Tang, N. (2025). SPOP Suppresses Hepatocellular Carcinoma Growth and Metastasis by Ubiquitination and Proteasomal Degradation of TRAF6. Cancer Science, 116(5), 1295-1307. https://doi.org/10.1111/cas.70025
Vancouver
Chang W, Feng K, Zhou P, Gong D, Wang K, Huang A, et al. SPOP Suppresses Hepatocellular Carcinoma Growth and Metastasis by Ubiquitination and Proteasomal Degradation of TRAF6. Cancer Science. 2025;116(5):1295-1307. doi:10.1111/cas.70025
BibTeX
@article{Chang2025,
author = {Chang, Wenyi and Feng, Kaiying and Zhou, Peng and Gong, Deao and Wang, Ke and Huang, Ailong and Wang, Kai and Tang, Ni},
title = {SPOP Suppresses Hepatocellular Carcinoma Growth and Metastasis by Ubiquitination and Proteasomal Degradation of TRAF6},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {5},
pages = {1295--1307},
doi = {10.1111/cas.70025}
}
EUVIMED